These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2373550)

  • 1. Effect of erythropoietin therapy on diet and dialysis clearances in hemodialysis patients.
    Kaupke CJ; Vaziri ND; Sampson JR; Atkins K
    Int J Artif Organs; 1990 Apr; 13(4):218-22. PubMed ID: 2373550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dialyzer urea and creatinine clearances are not significantly altered in erythropoietin treated maintenance hemodialysis patients.
    Delano BG; Lundin AP; Galonsky R; Quinn-Cefaro RM; Rao TK; Friedman EA
    ASAIO Trans; 1990; 36(1):36-9. PubMed ID: 2306389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary effects of erythropoietin treatment on metabolism and dialysis efficiency in stable hemodialysis patients.
    Buur T; Lundberg M
    Clin Nephrol; 1990 Nov; 34(5):230-5. PubMed ID: 2268981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of erythropoietin on the dialysis prescription.
    Van Wyck DB
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):71-5. PubMed ID: 1928083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of epoetin beta on dialyzer clearance and heparin requirements.
    Spinowitz BS; Arslanian J; Charytan C; Golden RA; Rascoff J; Galler M
    Am J Kidney Dis; 1991 Dec; 18(6):668-73. PubMed ID: 1962651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of erythropoietin treatment on urea kinetic parameters in hemodialysis patients.
    van Geelen JA; Nubé MJ; Zuurbier PA
    Clin Nephrol; 1991 Apr; 35(4):165-70. PubMed ID: 1855319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet.
    Allegra V; Martimbianco L; Vasile A
    Nephrol Dial Transplant; 1997 May; 12(5):924-32. PubMed ID: 9175044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case management of the anemic patient: epoetin alfa--focus on adequacy of dialysis.
    Erlich L
    ANNA J; 1993 Apr; 20(2):181-4. PubMed ID: 8512376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of hemodialysis patients treated with erythropoietin.
    Acchiardo SR; Quinn BP; Moore LW; Burk LB; Miles DE
    Am J Kidney Dis; 1991 Mar; 17(3):290-4. PubMed ID: 1996571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemodialysis efficiency after long-term treatment with recombinant human erythropoietin.
    Casati S; Campise M; Crepaldi M; Lobo J; Graziani G; Ponticelli C
    Nephrol Dial Transplant; 1989; 4(8):718-20. PubMed ID: 2510080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human erythropoietin correction of anemia. Dialysis efficiency, waste retention, and chronic dose variables.
    Paganini EP; Abdulhadi MH; Garcia J; Magnusson MO
    ASAIO Trans; 1989; 35(3):513-5. PubMed ID: 2688718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin.
    Eschbach JW; Kelly MR; Haley NR; Abels RI; Adamson JW
    N Engl J Med; 1989 Jul; 321(3):158-63. PubMed ID: 2747747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
    Boratyńska M; Szewczyk Z; Szepietowski T; Czyz W; Cybulski K; Bogucki J; Szczepański J
    Przegl Lek; 1990; 47(11):741-5. PubMed ID: 2098840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematocrit influence on peritoneal dialysis effectiveness during recombinant human erythropoietin treatment in patients with chronic renal failure.
    Ksiazek A; Baranowska-Daca E
    Perit Dial Int; 1993; 13 Suppl 2():S550-2. PubMed ID: 8399662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial.
    Kleinman KS; Schweitzer SU; Perdue ST; Bleifer KH; Abels RI
    Am J Kidney Dis; 1989 Dec; 14(6):486-95. PubMed ID: 2688405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin-induced changes in protein nutrition: quantitative assessment by urea kinetic modeling analysis.
    Canaud B; Bouloux C; Rivory JP; Taib J; Garred LJ; Florence P; Mion C
    Blood Purif; 1990; 8(5):301-8. PubMed ID: 2091690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical considerations of recombinant human erythropoietin therapy.
    Paganini EP; Latham D; Abdulhadi M
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):19-25. PubMed ID: 2667348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.